

Water-soluble geldanamycin analogue

Catalog # ant-dgl-5, ant-dgl-25

For research use only Version # 16G04-MM

PRODUCT INFORMATION

Contents:

17-DMAG is supplied as a lyophilized purple powder. It is available in two pack sizes:

- ant-dgl-5: 5 mg
- ant-dgl-25: 25 mg

Storage and stability:

- 17-DMAG is shipped at room temperature. Store lyophilized product at -20 °C. Protect from light. Lyophilized 17-DMAG is stable for 6 months when stored properly.

- Once solubilized 17-DMAG should be aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles. Protect from light. Resuspended product is stable for 3 months when properly stored.

QUALITY CONTROL

• Purity: ≥92% (UHPLC)

• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) is confirmed using HEK-Blue[™] TLR2 and HEK-Blue[™] TLR4 cells.


DESCRIPTION

17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, also known as alvespimycin) is the first water-soluble analog of 17-AAG. This Hsp90 inhibitor shows promise in preclinical models¹. 17-DMAG has excellent bioavailability, is widely distributed to tissues, and is quantitatively metabolized much less than is 17-AAG². Clinical studies have shown that alvespimycin (KOS-1022) has therapeutic effects and is well tolerated in patients with solid tumours, advanced solid tumours or acute myeloid leukaemia, indicating that it has potential to be a new drug of choice for cancer therapy².

1. Workman P., 2003. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 3(5):297-300. **2. Egorin MJ**, *et al.*, **2002.** Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49(1):7-19.

CHEMICAL PROPERTIES

<u>CAS number:</u> 467214-21-7 <u>Synonyms:</u> NSC 707545, Alvespimycin HCl <u>Formula:</u> C₃₂H₄₈N₄O₈ •HCl <u>Molecular weight:</u> 653.2 <u>Solubility:</u> H₂O (10 mg/ml) <u>Structure:</u>



The use of 17-DMAG is covered under US Patent 6,890,917 owned and licensed by the NIH to InvivoGen.

RELATED PRODUCTS

Product	Catalog Code
17-AAG (GA analogue)	ant-agl-5
FITC-Geldanamycin	ant-fgl-1
Geldanamycin	ant-gl-5



